Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Cabozantinib Plus Nivolumab in non–Clear-Cell RCC - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Cabozantinib Plus Nivolumab in non–Clear-Cell RCC

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Indication: Cabozantinib Plus Nivolumab in non–Clear-Cell RCC

New Indication: Cabozantinib Plus Nivolumab in non–Clear-Cell RCC
Study:
  • Single-arm, phase 2 trial
  • Non-clear cell RCC with 0-1 prior systemic therapies (n=47)
  • Cabozantinib 40 mg once daily + nivolumab 240 mg/2 weeks or 480 mg/4 weeks
Efficacy:
  • Median follow up: 13.1 mos
  • Papillary, unclassified, or translocation-associated RCC: ORR: 47% [32%-64%], mPFS:12.5 mos [6.3-16.4 mos), mOS:28 mos
Safety:
  • Grade >=3 AEs: 32%
  • Fatigue 57%, PPE 57%, diarrhea 53%

J Clin Oncol. 2022 Mar 17;JCO2101944.

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates

https://doi.org/10.1200/jco.21.01944

Reviewed by Hasan Cagri Yildirim, MD on Mar 28, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More